• 6_quinesSomos
  • 7_quienesSomos
ignore

Who We Are

The BAPP is a multi-disciplinary group focused on the fields of applied life sciences with an emphasis on bioanalysis, proteomics, and pharmacology.

Bioanalysis and Analytical Services Research Group
(Dr. Jordi Segura)

click here clic

The main scientific aim of the Bioanalysis Group consists of the research and development of analytical protocols, subject to strict quality control regulations, which can aid the detection and better understanding of the pharmacokinetics/pharmacology of the drugs present in biological fluids. The study objectives are new drugs such as those which some individuals, including sportspeople, tend to abuse.

The research group is fully equipped to carry out studies on these substances, with both high and low molecular weight, through the use of chemical methods (e.g. gas chromatography, liquid chromatography, different types of mass spectrometry (GC-MS, HPLC-MS, MS-MS) which include access to MALDI-OF and LC-Q-TOF MS) and biological methods (e.g. immunoassay, superficial plasmon resonance, electrophoresis, and isoelectric focusing).

Members of the Bioanalysis and Analytical Services Group run the Analytical Services Laboratory which holds all the Quality Accreditation needed to carry out its tasks (Accredited laboratory by ENAC with number nº 239/LE485 with UNE-EN  ISO/IEC 17025:2005, World Antidoping Agency (WAA), Association of Official Racing Chemists (AORC)). Some of its main activities include the Antidoping Laboratory, the Quality Control Program in the determination of drugs of abuse, and the development of information technology programs for the management of the laboratories (IMLIMS).

Human Pharmacology and Neurosciences Clinical Research Group
(Dr. Rafael de la Torre)

click here clic

The Human Pharmacology and Neuroscience Clinical Research Group (HPNCRG) forms part of the Neurosciences Program at the IMIM (Hospital del Mar Medical Research Institute) whose principal researchers are Dr. Rafael de la Torre and Dr. Magí Farré. The Program’s mission is to provide support to clinical research, the finality being a better understanding of mental and neurodegenerative disease and therapeutic solutions.

The HPNCRG at the IMIM began its activity at the Clinical Pharmacological Service at the Hospital del mar, Barcelona, in 1979. In that year the first intra-hospital detoxification unit for addiction was created in Spain. The initial (and still ongoing) areas of interest were Phase I and II clinical trials of new drugs, the clinical pharmacology of psychotropic substances, including drugs of abuse, studies of susceptibility to abuse of new studies, and studies on drug metabolism. The HPNCRG has, therefore, a history of more than 30 years in the clinical field of neuroscience. It manages the Clinical Research Unit of the IMIM where it carries out clinical studies and is located its analytical laboratory infrastructure. The research group is consolidated by the Catalan Generalitat (DIUE2009 SGR 718) forming part of the innovative technological network (TECNIO, ACC1Ó). Its researchers are integrated into the following networks and online research centers: the Addictive Disorders Network-ADN (ISCIII-FEDER-FIS-RTA RD06/0001/1009), The Spanish Platform for Clinical Trials -CAIBER (ISCIII-FIS-CAIBER CAI08/01/0024), and The Online Biomedic Research Center for the Physiopathy of Obesity and Nutrition -CIBERobn (CB06/03). HPNCRG researchers are members of the teaching staff at the Pompeu Fabra University and the Autonomous University of Barcelona for the degrees of Human Biology and Medicine in the fields of Pharmacology, Toxicology, and Bioethics.

Proteomics CRG/UPF
(Dr. David Andreu)

click here clic

Since our arrival at the PFU in 2002, the research group, with wide experience and dedication in the areas of chemistry and bioactive peptide applications, has expanded its activities to include proteomics. Within the field of peptide chemistry we are particularly interested in antibiotic peptides and vaccines with synthetic peptides. We have designed lead structures which have strong activity against bacteria, protozoa, and fungi. A number of these peptides are being currently evaluated for clinical strains of Acinetobacter baumannii, Leishmania donovani and other pathological agents. The group is also interested in the structural dissection of antimicrobial proteins found in higher plants (e.g. thionin, hevein) with a view to developing active minimalist versions. In the field of vaccines, it has developed functional synthetic replicas of the major antigenic sites of the foot and mouth disease virus which have been incorporated into various health benefits such as candidate vaccines.